Posttransplant administration of donor leukocytes induces long-term acceptance of kidney or liver transplants by an activation-associated immune mechanism.
Donor leukocytes play a dual role in rejection and acceptance of transplanted organs. They provide the major stimulus for rejection, and their removal from the transplanted organ prolongs its survival. Paradoxically, administration of donor leukocytes also prolongs allograft survival provided that they are administered 1 wk or more before transplantation. Here we show that administration of donor leukocytes immediately after transplantation induced long-term acceptance of completely MHC-mismatched rat kidney or liver transplants. The majority of long-term recipients of kidney transplants were tolerant of donor-strain skin grafts. Acceptance was associated with early activation of recipient T cells in the spleen, demonstrated by a rapid increase in IL-2 and IFN-gamma at that site followed by an early diffuse infiltrate of activated T cells and apoptosis within the tolerant grafts. In contrast, IL-2 and IFN-gamma mRNA were not increased in the spleens of rejecting animals, and the diffuse infiltrate of activated T cells appeared later but resulted in rapid graft destruction. These results define a mechanism of allograft acceptance induced by donor leukocytes that is associated with activation-induced cell death of recipient T cells. They demonstrate for the first time that posttransplant administration of donor leukocytes leads to organ allograft tolerance across a complete MHC class I plus class II barrier, a finding with direct clinical application.
Yan
Y
Y
Centenary Institute of Cancer Medicine and Cell Biology, and Departments of Surgery and Anatomical Pathology, Royal Prince Alfred Hospital, Sydney, Australia.
Shastry
S
S
Richards
C
C
Wang
C
C
Bowen
D G
DG
Sharland
A F
AF
Painter
D M
DM
McCaughan
G W
GW
Bishop
G A
GA
D000818:Animals; D017209:Apoptosis / Q000276:immunology; D002465:Cell Movement / Q000276:immunology; D006082:Graft Enhancement, Immunologic / Q000379:methods*; D006085:Graft Survival / Q000276:immunology*; D007275:Injections, Intravenous; D007371:Interferon-gamma / Q000096:biosynthesis / Q000235:genetics; D007376:Interleukin-2 / Q000096:biosynthesis / Q000235:genetics; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D017708:Leukocyte Transfusion; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation / Q000276:immunology*; D008221:Lymphoid Tissue / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D011184:Postoperative Period; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D023001:Transplantation Tolerance; D014184:Transplantation, Homologous
D007376:Interleukin-2; D012333:RNA, Messenger; D007371:Interferon-gamma